Long COVID Treatment Trials – Finally – Set to Start

In December 2020, Congress approved $1.15 cardinal for the NIH to probe and trial treatments for agelong COVID. The caller objective trials are signifier II, meant to trial information and effectiveness. But immoderate advocates are acrophobic the process is inactive moving excessively slowly.